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Carcinogen-induced formation of DNA adducts and other types of DNA lesions are the critical molecular events in the initiation of chemical
carcinogenesis and modulation of such events by chemopreventive agents could be an important step in limiting neoplastic transformation in vivo.
Vanadium, a dietary micronutrient has been found to be effective in several types of cancers both in vivo and in vitro and also possesses profound
anticarcinogenicity against rat models of mammary, colon and hepatocarcinogenesis. Presently, we report the chemopreventive potential of
vanadium on diethylnitrosamine (DEN)-induced early DNA damages in rat liver. Hepatocarcinogenesis was induced in male Sprague–Dawley rats
with a single, necrogenic, intraperitoneal (i.p.) injection of DEN (200 mg/kg body weight) at week 4. There was a significant induction of tissue-
specific ethylguanines, steady elevation of modified DNA bases 8-hydroxy-2′-deoxyguanosines (8-OHdGs) (P<0.0001; 89.93%) along with
substantial increment of the extent of single-strand breaks (SSBs) (P<0.0001) following DEN exposure. Supplementation of 0.5 ppm of vanadium
throughout the experiment abated the formations of O6-ethylguanines and 7-ethylguanines (P<0.0001; 48.71% and 67.54% respectively),
8-OHdGs (P<0.0001; 81.37%), length:width (L:W) of DNA mass (P<0.01; 62.12%) and the mean frequency of tailed DNA (P<0.001; 53.58%),
and hepatic nodulogenesis in preneoplastic rat liver. The study indicates that 0.5 ppm vanadium is potentially and optimally effective, as derived
from dose–response studies, in limiting early molecular events and preneoplastic lesions, thereby modulating the initiation stage of
hepatocarcinogenesis. Vanadium is chemopreventive against DEN-induced genotoxicity and resulting hepatocellular transformation in rats.
© 2006 Published by Elsevier B.V.Keywords: Vanadium; Hepatocarcinogenesis; DNA adduct; Ethylguanines; 8-OHdGs; DNA strand-break1. Introduction
Vanadium, a group VB, first transition series, ultra-trace
element (molecular weight 50.942) with various oxidation
states ranging from −1 to +5, is an endogenous constituent of
plants, animals and most mammalian tissues [1,2]. This dietary
micronutrient is believed to have a regulatory role in biological
systems and is very probably an essential element, just like
other 40 essential micronutrients, requiring small amount for
normal cell metabolism as well as for proper growth and
development of mammals [1–3]. It influences the behaviour of
enzymes, regulates the activities of second messengers, signal⁎ Corresponding author. Tel.: +91 33 2414 6393; fax: +91 33 2414 6393.
E-mail address: mcbiochem@yahoo.com (M. Chatterjee).
0925-4439/$ - see front matter © 2006 Published by Elsevier B.V.
doi:10.1016/j.bbadis.2006.10.019transduction cascades and carbohydrate metabolism, mimics
insulin and growth factor activities, stimulates protein tyrosine
kinase and inhibits phosphotyrosine phosphatases and mod-
ulates gene expression [4]. This nutritional element has further
been considered as a potential agent owing to its ability to
prevent regular wear and tear of the genome and accordingly, it
is involved in various DNA maintenance reactions and thereby
may prevent genomic instability leading to cancers [2,5].
Vanadium compounds have been found to be potentially
effective against murine leukaemia, fluid and solid Ehrlich
ascites tumour [6], murine mammary adenocarcinoma and
HEp-2 human epidermoid carcinomal cells [7] and human
carcinomas of lung, breast, and gastrointestinal tract [Köpf-
Maier, 1994] [8]. Furthermore, in vivo and in vitro antitumour
activities of different vanadium compounds have been
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found strong antitumour chemopreventive activities of vanadyl
complexes of 1,10-phenanthroline [VO(Phen)2+] and related
derivatives against human nasopharyngeal carcinoma and the
observed effects were found to be superior than the chemother-
apeutic drug, cis-diamminedichloroplatinum. Recently, orga-
nometallic vanadocene compounds have been found to be
potent anti-proliferative agents disrupting bipolar mitotic
spindle formation and inducing cell cycle growth arrest in
cancer cell lines [13]. Bis(4,7-dimethyl-1,10-phenanthroline)
sulfatooxovanadium(IV) or Metvan is equally the most
promising multitargeted antitumour vanadium complex with
apoptosis-inducing property against human leukemia cells,
multiple myeloma cells and a number of solid tumours derived
from cancer patients [14]. Again, bisperoxovanadium (bpV)
compounds as irreversible protein tyrosine phosphatase inhibi-
tors with broad-spectrum antineoplastic activities are also under
investigation [15].
A series of studies from our laboratory has shown that
supplementation of 0.5 ppm vanadium in drinking water was
quite effective in suppressing chemical hepatocarcinogenesis in
rats without any toxic manifestations. Reports indicate that the
anti-tumour effect of 0.5 ppm vanadium may be mediated
through selective induction and stabilization of hepatic xeno-
biotic biotransforming enzymes [16], inhibitions of γ-glutamyl
transpeptidase (GGT)- [17] and placental glutathione S-
transferase (PGST)-positive foci [18], suppression of 2-AAF-
induced DNA–protein crosslinks formation [19] and reduction
of proliferating cell nuclear antigen immunoreactivity [20] in
preneoplastic rat liver. The 0.5 ppm (4.27 μmol/L) concentration
of vanadium was chosen exclusively by dose–response studies
made in our laboratory much earlier in untreated normal rats with
respect to inductions of hepatic glutathione (GSH) and
Glutathione S-transferase (GST) activity [21]. This particular
dose of 0.5 ppm has been found to be well tolerated and suitable
with adequate growth responsive effect. Vanadium at this
concentration was also found to be devoid of toxicity, since no
histological abnormalities or histopathological changes were
noticed neither in the liver and kidney nor in the stomach of the
rats studied [21]. In this paper, we have further detailed the dose–
response studies of vanadium, which we have made in recent
times with respect to carcinogen-induced DNA damage and
development of preneoplastic lesions (nodulogenesis) in Spra-
gue–Dawley rat liver chemical carcinogenesis model.
We preferred rat model over mouse, because: first, many
mouse strains seem to yield high rates of spontaneous liver
tumours. Spontaneous liver tumours in rats are more rare [22].
High background incidence of tumours in mice liver may also
confound the interpretation of dose response in chemical
carcinogenicity studies in murine liver [23]; second, rat liver is
a frequent target for the development of chemically induced
cancer in rodents, and it is the most commonly used
experimental model for investigating multistage carcinogenesis
in vivo [24]. Furthermore, in the rat liver carcinogenesis models,
a variety of enzyme-altered condition has been studied for their
relevance to preneoplastic and neoplastic developments. For
example, an immunohistochemically demonstrable enzymemarker, PGST has been utilized for the identification of liver
preneoplastic focal lesions. In contrast, no equivalent markers
for preneoplastic foci are available for mice [25]. In addition, rats
have got several other advantages [26], like (a) the many
similarities between the rat and human metabolic pathways; (b)
the many similar anatomical and physiological characteristics
that allow for comparisons in pharmacokinetics; (c) the short life
span, especially for carcinogenesis study, which allows
observation of DNA transformation from its initial stage to
full-blownmalignancy; (d) high levels of natural killer (NK) cell
immunity; and (e) the easy availability, ease of breeding, and the
existence of a large database to enable comparison of present to
reported literature findings.
Presently we extend our study further to have insights into
the early molecular events associated with the ‘initiation’ of
carcinogenesis in order to have an understanding of the
underlying basis of chemopreventive potential of vanadium in
modulating the initiation event and thereby limiting DNA
damage in vivo. Experimental hepatocarcinogenesis can be
induced by various chemical carcinogens, such as, diethylni-
trosamine (DEN), 2-acetylaminofluorene (2-AAF), aflatoxin
B1. DEN is a potent hepatocarcinogen in rats influencing the
initiation stage of carcinogenesis during a period of enhanced
cell proliferation induced by hepatocellular necrosis and
forming DNA–carcinogen adducts, inducing DNA-strand
breaks and in turn hepatocellular carcinomas (HCCs) without
cirrhosis through the development of putative preneoplastic
focal lesions [27]. Formation of DNA–carcinogen adduct is
therefore a prerequisite for chemical carcinogenesis. Besides,
carcinogen-induced alterations of the DNA helix include helical
distortion, oxidative base modifications, single-strand and
double-strand breaks, DNA–DNA inter-strand as well as
DNA–protein crosslinks and chromosomal aberrations, and as
such carcinogen-induced DNA damage has been implicated as
one of the early steps in chemical carcinogenesis [28]. Among
the most abundant and mutagenic oxidative base modifications,
8-hydroxy-2′-deoxyguanosine (8-OHdG), produced by the
oxidation of deoxyguanosine is considered as the most sensitive
and potential marker of oxidative DNA damage [29]. It has been
shown that 8-OHdG is closely associated with certain diseases,
including cancer, and is produced in various experimental
models of chemical carcinogenesis [30,31]. Thus, studying the
pattern of changes in the levels of tissue-specific DEN-induced
alkylated DNA adducts as well as 8-OHdGs following
carcinogen assaults could be quite relevant in understanding
the ‘initiation’ event of carcinogenesis. 32P-post-labeling and
high performance liquid chromatography (HPLC) provide
sensitive techniques to quantify respectively ethylated DNA
bases and oxidative bases in tissue DNA samples. Besides 8-
OHdGs, the magnitude of DNA single-strand breaks (SSBs) is a
measure of genotoxicity following carcinogen exposure. The
inability of cells to repair such damage adequately is a putative
causal event in chemical carcinogenesis [31,32]. Single Cell Gel
Electrophoresis (SCGE) or the Comet assay, in particular the
alkaline version of the assay, has become a popular method for
the sensitive analysis, detection and quantitation of genotoxic
DNA damage caused by various chemical and physical agents.
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and excision repair sites in individual interphase cells [33].
The principal aim of the study therefore is to find out the
possible mechanism by which vanadium exerts antigenotoxic
and thereby anti-hepatocarcinogenic effects in vivo. The study
focuses the interaction of the dietary micronutrient vanadium
with the critical molecule like DNA and inhibition of early
DNA damages by this trace metal in modulating the initiation
event of carcinogenesis. Thus, the present study was designed
with two basic objectives: first, to assess the roles of DNA
adducts, 8-OHdGs and SSBs on the hepatocarcinogenesis
initiation; and second, to find out the chemopreventive potential
of the optimum and effective dose of vanadium through dose–
response studies in limiting the extent of molecular markers and
resulting expression of premalignant phenotype in a rodent
model of experimental hepatocarcinogenesis.
2. Materials and methods
2.1. Materials and maintenance of animals
All the reagents and biochemicals, unless otherwise mentioned were
obtained from Sigma Chemicals Co. (St. Louis, MO) and E. Merck (Franfurter
Straβe, Darmstadt, Germany).Fig. 1. The basic experimental reMale Sprague–Dawley rats obtained from the Indian Institute of Chemical
Biology (CSIR), Kolkata, India weighing 80–100 g at the beginning of the
experiments were used throughout the study. The animals were acclimatized to
standard laboratory conditions (temperature 24+1 °C, relative humidity 55+5%
and a 12 h photoperiod) and were housed in Tarson Cages (four to five rats per
cage) for 1 week before the commencement of the experiment. During the entire
period of study, the rats were supplied with a semi-purified basal diet (Lipton
India Ltd., Mumbai, India) and water ad libitum. The recommendations of
Jadavpur University's “Institutional Animal Ethics Committee” [“Committee for
the Purpose of Control and Supervision of Experiment on Animals” (CPCSEA
Regn. No. 0367/01/C/CPCSEA) INDIA] for the care and use of laboratory
animals were strictly followed throughout the study and the particular project was
approved by the Chairman of the Committee.
2.2. Experimental regimen
Different sets of rats were randomly divided into four experimental groups
as illustrated in Fig. 1 for carrying out molecular studies (short-term studies).
Groups C and D rats were the DEN-treated groups that received a single,
necrogenic, intraperitoneal (i.p.) injection of DEN (200 mg/kg body weight in
0.9% saline) at 9 weeks of age i.e. at week 4 of experimentation, whereas groups
A and B rats were the normal and vanadium controls respectively. Group C rats
were the DEN control; while Group B (vanadium control) and D (vanadium+
DEN) rats received 0.5 ppm (4.27 μmol/L) vanadium as ammonium
metavanadate (NH4VO3,+V oxidation state) in terms of the salt weight in
drinking water, ad libitum starting 4 weeks prior to DEN initiation and stopped
at week 4 prior to DEN initiation. Solutions of vanadium (pH 7.0) were renewedgimen for molecular studies.
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of the animals from each group were recorded every second day. All the rats
were sacrificed by decapitation between 0900 and 1100 h under proper light
ether anesthesia after week 4 at various time points to carry out experimenta-
tions. All the animals were fasted over night before sacrifice. For the estimation
of ethylguanines and 8-OHdGs, rats were sacrificed after 3, 6, 12, 18, 24, and
48 h and for DNA strand-breaks after 18–20 h of DEN injection; livers were
promptly excised and hepatic DNAwas isolated. For evaluation of preneoplastic
lesions, all the four groups of rats were sacrificed after week 21 (long-term
study), maintaining groups B and D rats with 0.5 ppm of vanadium for 20
consecutive weeks and DEN administration to groups C and D rats at week 4.
Following 3 weeks of recovery, all the DEN-initiated rats were given
phenobarbital (PB) (0.05% in basal diet), 5 days a week till week 20.
2.3. Dose–response studies of vanadium
Dose–response studies of vanadium were carried out in the group D rats in
two time courses: (a) short-term study using in vivo DNA damage by the
alkaline Comet assay and (b) long-term study involving evaluation of
preneoplastic lesions. We have used seven different concentrations (μmol/L)
(0.5, 1, 2, 4, 6, 8, and 16) of vanadium for both the studies, a and b. The detail of
the Comet assay is given in Section 2.7. For the rats sacrificed after 21 weeks,
the livers were promptly excised, blotted, and weighed. The livers were then
examined macroscopically on the surface as well as in 3-mm cross sections for
gross visible persistent nodules (PNs), which represent focal proliferating,
hepatic lesions with a low tendency for spontaneous regression [34]. The PNs
were easily identified from the reddish-brown non-nodular surrounding
parenchyma (NNSP) by their greyish-white color which clearly differentiated
them from the adjacent liver tissue.
2.4. Histopathology
After draining the blood, liver slices were taken from each lobe of the liver.
The tissue slices were at once immersed in 10% buffered formalin solution for
fixation, dehydrated with graded ethanol solutions from 50% to 100%, and then
embedded in paraffin. Sections of 5 μm in thickness were cut and stained with
haematoxylin and eosin [35]. The histopathological slides were observed under
an ADCON 5591 (ADCON, Cleveland, USA) photomicroscope. All the slides
were examined without prior knowledge of the treatment given to the animals
from which the tissue samples under investigation were taken.
2.5. Analysis of tissue-specific DNA adducts
The tissue DNA samples (5 μg) were enzymatically digested to deoxy-
nucleoside 3′-monophosphates with 0.21 U micrococcal nuclease and
0.174 U spleen phosphodiesterase at 37 °C for about 4.5–5 h [36]. After
treatment of DNA samples with 5 μg nuclease P1 for 30 min at 37 °C, the
hydrolysate enriched in adducted nucleotides, viz., O6-Ethylguanine (O6eGua)
and 7-Ethylguanine (e7Gua) was then labeled by incubation with 24 μCi carrier-
free [γ-32P]ATP (3000 Ci/mM) and 10 U T4 polynucleotide kinase at 37 °C for
30 min in 25 μL of bicine buffer mixture [36,37]. Resolution of 32P-labelled
digests treated with nuclease P1 was carried out by multidirectional
polyethyleneimine-cellulose Thin-Layer Chromatography (TLC) fingerprinting
using the contact transfer technique [38]. The solvent systems selected were:
1 M sodium phosphate, pH 6.8; 4 M lithium formate, 7.5 M urea, pH 3.5; 0.65M
LiCl, 0.45 M Tris–HCl, 7.7 M urea, pH 8.0; 1.7 M sodium phosphate, pH 5.0.
Analysis of total nucleotides was achieved by direct 32-P labeling of another
aliquot of the DNA digest mentioned as above, followed by one-dimensional
TLC of the labeled digest. The adduct spots were detected by autoradiography
from 72 to 96 h at −80 °C using Kodak XAR-5 films and intensifying screens.
DNA adduct concentration was estimated from the measurement of radioactivity
in adduct as well as in total nucleotides and the result was expressed as fmol of
adducts/μg DNA, considering 1 μg of DNA=0.3×107 fmol nucleotides [39].
2.6. Measurement of 8-OHdGs
DNA was extracted from perfused livers of different groups of rats with
chloroform only (because phenol exposure would artificially increaseoxidative base concentration in DNA samples) following the protocol of
Dahlaus and Appel [40] with minor modifications. Briefly, one volume of
nuclear fraction obtained from liver homogenate by centrifugation was mixed
with eight volumes of extraction buffer (1 M NaCl, 10 mM Tris–HCl, 1 mM
EDTA, 2% SDS, pH 7.4) and one volume of chloroform:isoamyl alcohol
(12:1 v/v). After vigorous shaking, the aqueous phase was separated by
centrifugation and DNA in TE buffer was incubated with a mixture of RNase
T1 and RNase A. Finally, DNA was extracted again and precipitated with
chilled ethanol. DNA concentration was estimated spectrophotometrically
using 20 A260 U/mg.
200 μg of DNA (4–5 A260 U/200 μL) in 40 mM Tris, pH 8.5, containing
10 mMMgCl2 was first denatured by heating at 95 °C for 3 min and then cooled
on ice. The extracted DNA was digested into deoxynucleosides by incubation
for 2 h at 37 °C with a mixture of DNase I (from bovine pancreas; 200 U/mg
DNA), spleen exonuclease (0.01 U/mg), snake venom exonuclease (0.5 U/mg),
and E. coli alkaline phosphatase (10 U/mg) [41]. The incubation was terminated
with acetone to precipitate proteins and DNA was dissolved in distilled,
deionized water.
The content of 8-OHdGs in the digested DNA was measured by an
electrochemical detector (ECD) coupled with high performance liquid
chromatography (HPLC-ECD system) [42] which consisted of a Waters 600E
pump, a Whatman Partisphere-5 C18 column and a UV detector (Hewlett-
Packard 1050, 254 nm) connected to an ECD (Hewlett-Packard 1049A) in series
for monitoring deoxyguanosines (dGs) and 8-OHdGs respectively. The mobile
phase consisted of 10 mM NH4H2PO4, 10 mM KCl, 1 mM EDTA and 10%
aqueousmethanol (pH 4.7) and the flow rate was set at 1.0ml/min. The content of
8-OHdGs in each DNA sample was expressed as the molar ratio of 8-
OHdG×105 to total dGs based on the peak height of authentic 8-OHdG with EC
detector and the UVabsorbance at A254 of dGs [42]. On prolonged incubation of
the DNA sample with E. coli alkaline phosphatase under the conditions
described above, the content of 8-OHdGs increased at the rate of 0.4+0.1
residue/105 dG/h. Therefore this blank value for 8-OHdG was subtracted from
the observed data. In Fig. 4, background 8-OHdG levels in control DNA (0.8–1.2
residue/105 dG) were subtracted.
2.7. Estimation of in vivo DNA strand-breaks by Comet assay
In vivo DNA strand-breaks were measured in liver samples using the
alkaline Comet assay, essentially as described by Olive et al. [33]. The tissues
were homogenized in phosphate-buffered saline (PBS; pH 8.0) under
refrigeration and filtered. Cell viability was determined by the trypan blue
method. 4 μL of the homogenized tissue was then transferred to 50 μL of fresh
PBS (pH 7.5), washed, suspended in 150 μL of 1% low melting point agarose
at 37 °C, and pipetted onto an agarose-precoated glass microscope slide. Slides
were prepared in triplicate. The slides were immersed for 60 min in freshly-
prepared ice-cold lysis solution (2.5 M NaCl, 0.1 M Na2EDTA, 10 mM Tris–
HCl (pH 10), 10% DMSO and 1% Triton X-100) at 4 °C in the dark, washed,
and then subjected to horizontal electrophoresis using freshly made buffer
(0.3 M NaOH and 1 mM Na2EDTA, pH>13). After electrophoresis, the slides
were stained with 5 μg/ml ethidium bromide and viewed under a Zeiss
fluorescence microscope equipped with a green excitation filter and a 590 nm
barrier filter. Routinely 150 cells (50 cells/slide) were screened per liver
sample from each animal and then the mean value and standard error of mean
(SEM) were calculated from the 15 values obtained from 15 rats under
experimentation. Nucleoid DNA extends under electrophoresis to form ‘comet
tails’, and the length of the comets was evaluated for determination of the
percentage of tailed DNA. This value is linearly related to the frequency of
DNA breaks [33].
2.8. Statistical analysis
The data were analyzed using the GraphPad Prism software package,
Version 4.01 (Barcode Softwares, Baltimore, MD). Student's t-test was
performed to compare sample means and the results were expressed as
Mean+S.E. One-way ANOVA followed by Tukey–Kramer multi-comparison
test was also performed to evaluate the changes among different time intervals
within a variable using the error calculated from ANOVA. Statistical signi-
ficance was set at P<0.05 for all the values.
Table 1
Dose–response studies of vanadium with respect to nodular hyperplasia in
rat liver treated with diethylnitrosamine (200 mg/kg body weight) and
phenobarbital
Vanadium
concentrations
(μmol/L)
No. of rats
with nodules
Nodule
incidence
(%)
Total no.
of nodules
Nodule a
multiplicity
0.5 15 100.00 167 11.13±2.76 b
1.0 13 86.66 139 10.70±1.68
2.0 9 60.00 82 9.11±3.64
4.0 4 26.66 17 4.25±1.48
6.0 4 26.66 17 4.25±1.59
8.0 5 33.33 21 4.20±2.82
16.0 9 53.33 76 8.44±2.71
a Average number of nodules/nodule bearing liver.
b Values represent Mean±S.E. (n=15).
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During the entire period of study, no differences in food
and water consumption were observed among the various
groups of animals. Food and water intakes were 10.7–12.8 g
100 g−1 day−1 and 8–10 ml/day/rat respectively for all rat
groups.
3.1. Determination of optimum dose of vanadium from
dose–response studies
Fig. 2 reveals the dose–response curve of vanadium at 7
specified doses in relation to DEN-induced early DNA damage
in the preneoplastic liver of group D rats. The pattern of the
curve shows that, there was almost 82% of tailed DNA in the
liver of the rats as measured by the in vivo Comet assay
following 4 weeks of 0.5 μmol/L of vanadium pre-treatment.
Gradual increase in vanadium concentration (up to 4 μmol/L)
resulted in an almost linear decrease in the frequency of tailed
DNA. At 4.27, 6 and 8 μmol/L of vanadium concentrations, a
steady maintenance of the dose–response curve was noticed at
these points and no further reduction/protection in DNA
damage by supplementary vanadium was observed. This
indicates that, vanadium at these concentrations exerts optimum
chemoprotective effect in vivo. However, further rise in
vanadium concentration beyond 8 μmol/L (e.g. 16 μmol/L)
shows (slightly) elevated pattern in the nature of the curve,
which suggests that vanadium treatment beyond 8 μmol/L may
become cytotoxic.
Again, from Table 1, it is further evident that vanadium
treatment for 20 consecutive weeks in a long-term experimental
regimen at the concentration of 4.27 μmol/L exerts optimum
chemopreventive effect in inhibiting hepatic preneoplastic
lesions in terms of nodule incidence and total number. Further,
with this particular dose of vanadium, there were no
toxicologically significant changes in hematology, clinical
chemistry and clinical enzymology, body and relative organ
weights etc. Based on these findings, we have used 4.27 μmol/LFig. 2. Dose–response curve defines the relationship between vanadium
concentrations (μmol/L) and genotoxic DNA damage (%) following a single,
necrogenic dose (200 mg/kg body weight) of diethylnitrosamine (DEN)
injection in rat liver. Each bar indicates Mean±S.E. [n=15].or 0.5 ppm as the optimum, well tolerated and pharmacologi-
cally effective dose of vanadium in our study.
3.2. Histopathological profile of liver
Phenotypically altered hepatocyte populations including
persistent nodules (PNs) were found scattered in the livers of
DEN-PB-treated groups (i.e., groups C and D); but no such
alterations were noticeable in untreated normal control (group
A; Fig. 3A) or in the vanadium control group (group B) (figure
not shown). In group C rats (Fig. 3B, C), a gross alteration in
hepatocellular architecture was found and hepatocytes
appeared oval or irregular in shape. The altered hepatocytes
of foci and nodules were found consistently enlarged with more
than one nucleus, which were moreover largely vesiculated
with centrally located nucleoli. Some nuclei in the cells were
large and hyperchromatic (basophilic) (Fig. 3C), indicating
prominent hyperbasophilic preneoplastic focal lesions around
the portal vein that were clearly distinguishable from the
NNSP. Extensive vacuolation was observed in the cytoplasm
around the nucleus with masses of acidophilic (eosinophilic)
material and a number of prominent clear cell foci. In contrast,
the cellular architecture of hepatic lobules seemed to be almost
like that of normal liver in group D (Fig. 3D) that received
0.5 ppm of vanadium supplementation during the entire period
of study, i.e. for 20 consecutive weeks. Liver sections from this
group presented only a few clear cell foci. The cells were
generally filled with cytoplasmic material and were less
vacuolated. The size of the nuclei was essentially the same as
that of normal cells and cells with two nuclei were considerably
fewer than in group C rats.
3.3. Effect of vanadium on the levels of formation of ethylated
DNA adducts in rats induced by DEN at different time points
Fig. 4 shows the kinetics of formation and persistence of
ethylated DNA adducts (O6eGua and e7Gua) in rat liver after
a single, necrogenic, i.p. injection of DEN at sequential time
points. The levels of ethylguanine formation in rat liver
DNA have been plotted as a function of time following
carcinogen assault. The formation of O6eGua (Fig. 4A) and
Fig. 3. Contiguous liver sections of rats being sacrificed after 21 weeks, showing (A) normal hepatocellular architecture (Group A, normal control) depicting
hepatocytes radiating from the central vein; (B, C) aberrant hepatocellular phenotype (Group C, DEN+PBControl) with prominent hyperbasophilic preneoplastic focal
lesions and the presence of eosinophilic and clear cell foci following a single, necrogenic, inraperitoneal injection of diethylnitrosamine (DEN) (200 mg/kg body wt.) at
week 4 and application of phenobarbital (PB) (0.05% in basal diet) thereafter on and from week 8; and (D) almost normal hepatocellular architecture (Group D,
Vanadium+DEN+PB) following DEN+PB regimen along with continuous supplementation of 0.5 ppm vanadium starting the application 4 weeks before initiation
and continued till 20 weeks. B—Basophilic Foci; CV—Central Vein; C—Clear Cell Foci; E—Eosinophilic Cell; M—Mixed Cell; PV—Portal Vein; S—Sinusoid.
Mag. (A) H&E ×150; (B–D) H&E ×450.
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apparently formed simultaneously over the given time
periods. The time dependency of hepatic DNA alkylation
to reach a maximal level ranged from 3 to 18 h following
DEN exposure. After 18–20 h, the rate of formation of
ethylated adducts started to decline in both the DEN-treated
groups (groups C and D), indicating a prominent role of
vanadium against adduct formation. There was a significant
reduction (P<0.0001) in O6eGua level in vanadium-supple-
mented rat liver (group D) at 18 h (21.25%), 24 h (26.87%)
and 48 h (48.71%) when compared to DEN control.
However in case of e7Gua, vanadium treatment caused a
significant reduction (P<0.0001) in adduct level at 48 h
(67.54%). Ethylguanines were not detected in Groups A
(normal control) and B (vanadium control). One way
ANOVA followed by Tukey–Kramer multi-comparison test
showed significant changes in the pattern of O6eGua and
e7Gua adduct levels during six sequential time points studied
herein (i.e., after 3, 6, 12, 18, 24 and 48 h of DEN injection)in group C (DEN control) [P<0.0001; Computed F is much
more greater than the Critical F0.05 (2.32) which amounts to
289.99 and 279.97 for O6eGua and e7Gua respectively; table
not shown] as well as in group D (vanadium+DEN)
[P<0.0001; Computed F is much more greater than the
Critical F0.05(2.32) which amounts to 292.30 and 132.66 for
O6eGua and e7Gua respectively; table not shown].
3.4. Effect of vanadium on the levels of formation of 8-OHdGs
in rat liver induced by DEN at different time points
The formation of 8-OHdGs in DNAwas significant and rapid
and the time dependency of hepatic DNA base lesion to reach a
maximal level ranged from 3 to 18 h following DEN exposure
(P<0.0001; 89.93%) (Fig. 5) when compared to group A. After
that, there was a steady maintenance of oxidative adducts in the
carcinogen control group (group C). On the other hand, there
was a significant reduction in 8-OHdG levels in vanadium
supplemented rat liver (group D) at 18 h (P<0.02; 28.03%),
Fig. 4. Levels of formation and persistence of ethylated DNA adducts, namely
(A) O6-ethylguanine (O6eGua) (B) 7-ethylguanine (e7Gua) in rat liver at
sequential time points in presence (Group D) or absence (Group C) of 0.5 ppm
vanadium supplementation following a single, necrogenic dose (200 mg/kg
body weight) of diethylnitrosamine (DEN) injection. Each bar indicates Mean±
S.E. [n=15]. (A) *P<0.01 at 3 h and **P<0.0001 at 18, 24 and 48 h; and (B)
#P<0.001 at 12 h, $P<0.05 at 18 and 24 h and **P<0.0001 at 48 h after DEN
injection when compared to DEN Control (Group C).
Fig. 5. Levels of formation and persistence of oxidative DNA bases 8-OHdGs in
rat liver at sequential time points in presence (Group D) or absence (Group C) of
0.5 ppm vanadium supplementation following a single, necrogenic dose
(200 mg/kg body weight) of diethylnitrosamine (DEN) injection. Each bar
indicates Mean±S.E. [n=15]. ^P<0.0001 when compared with Normal Control
(Group A) at 6, 12, 18, 24 and 48 h of DEN injection; $P<0.02, #P<0.001 and
*P<0.0001 respectively at 18, 24 and 48 h after DEN injection when compared
with DEN Control (Group C).
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compared to DEN control. One-way ANOVA showed sig-
nificant changes in the pattern of 8-OHdG levels [P<0.0001;
Computed F is much greater than the Critical F0.05 (2.32) which
amounts to 55.17 (group C) and 232.29 (group D); table not
shown] during six sequential time points, which suggests a
prominent role of 8-OHdG in carcinogenesis and its modulation
by vanadium.
3.5. Effect of vanadium on hepatic DNA damage
The mean length to width (L:W) ratio of the DNA mass
indicating the extent of DNA damage was increased in the
carcinogen control group (Group C) in comparison with the
normal control (Group A) (P<0.0001; Fig. 6A). There was also
a significant increase in the frequency of tailed DNA in Group C
rats compared to Group A rats (P<0.0001; Fig. 6B). A short-
term treatment with vanadium (Group D) reduced the L:W ratio
of DNA mass (62.12% reduction; P<0.01) and the mean
frequency of tailed DNA (53.58% reduction; P<0.001)
compared to that of Group C carcinogen control rats.4. Discussion
We report here the chemopreventive potential of low dose of
vanadium in inhibiting DNA adducts and preventing oxidative
DNA damages during the early stages of hepatocarcinogenesis
in rats. Vanadium supplementation has been found to inhibit the
formation of ethylguanines, viz., O6eGua and e7Gua, tissue-
specific oxidative DNA bases 8-OHdGs, and SSBs in
hepatocytes. The results thus indicate that, vanadium at the
0.5 ppm dose, as derived from dose–response studies exerts
potential antigenotoxic effect against DEN-induced initiation of
hepatocarcinogenesis by inhibiting the formation of DNA
adducts and resulting DNA damage in vivo.
0.5 ppm vanadium that we have used is a “low dose” of
vanadium. It is mentioned in the literature that at least 5 ppm
vanadium in drinking water for entire the life-term is absolutely
devoid of any symptoms or signs of toxicity [43] which is 10
times greater than the dose used in our present study. Moreover,
vanadium at a dose of 6 mg V/kg diet (120 μmol V/kg)
administered to Wistar rats in drinking water did not produce
any toxicity [44] and also no adverse symptoms were noted in
rats providing diets containing up to 50 ppm of vanadium [45].
Moreover, the dose used in our study is 600 times less than the
toxic dose as reported by several workers in rat models [46–48].
Again, we admit that toxicity becomes more relevant only when
it comes to human intervention studies, because doing ten
thousands of animal experimentations might not be adequate to
comment on human toxicity assuming the human exposure
levels. In humans, treatment for 6–10 weeks with 4.5–18 mg
vanadium/day produced only slight toxicity that too in the form
of cramps and diarrhoea [49]. Again, administration of 4.5 mg
vanadium/day for 16 months to patients showed no signs of
Fig. 6. Effect of 0.5 ppm vanadium on the (A) Length:Width of DNA mass, and
(B) Percentage of Tailed DNA in liver of rats 18–20 h after a single, necrogenic
dose (200 mg/kg body weight) of diethylnitrosamine (DEN) injection at week 4
of the experimental protocol. Each column and bar indicates Mean±S.E.
[n=15]. **P<0.0001 (Fig. 4A and B) when compared with normal control
(Group A); #P<0.01 (Fig. 4A) and $P<0.001 (Fig. 4B) when compared with
DEN control (Group C).
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have also demonstrated a high tolerance for oral vanadium at
pharmacological doses greater than 100 times the usual dietary
intake [51,52]. Thus, when considering ingestion of up to
125 mg vanadium per day or 8300 mg in 3 months caused only
cramps and transient diarrhoea without any other serious toxic
manifestations [49], it is evident that 0.5 ppm is really a “low”
dose of vanadium used in our experiment. This particular low
dose of vanadium results in anticarcinogenicity without any
toxicity whatsoever. Therefore, this dose is very much safe and
effective pharmacologically.
Even though not all the hepatocyte nodules become
malignant during the life span of the animals, numerous
observations support the concept that the hyperplastic/
neoplastic nodules are the precursors of hepatocellular
carcinoma [53]. In view of this, inhibition of nodule inci-
dence and enhancement of their regression by 0.5 ppm ofsupplementary vanadium, as observed in our study may be
important for cancer chemoprevention. This could be
explained in the light of the fact that, although the precursor
lesions were still present in the livers of vanadium treated rats,
their growth rates slowed to such an extent that the appearance
of visible persistent nodules was delayed beyond the
experimental end point owing to an increased latency period
[54]. Histopathological impressions further indicate that the
hyperplastic nodular hepatocytes formed solid aggregates of
one or more cells thick, the prominent “hyperbasophilic focal
lesion” mainly around the portal vein in carcinogen-treated
rats. The clear and acidophilic cells primarily form AHF,
which are considered to be the small “preneoplastic focal
lesions” that lead to malignant transformation in later stages of
carcinogenesis with the formation of neoplastic nodules and
ultimately hepatocellular carcinomas [55]. Thus, the majority
of the neoplastic nodules consist of a mixture of preneoplastic,
truly neoplastic and diverse intermediate cells. However, long-
term vanadium treatment resulted in reduced hepatocyte
aggregation and basophilicity with a reversal of heterogeneity
towards normal cytology. Histopathological findings as an
end-point biomarker primarily confirm the chemopreventive
potential of vanadium in inhibiting hepatocellular preneoplas-
tic lesions at the optimum dose (0.5 ppm or 4.27 μmol/L) used
in our study. Additionally, dose–response studies of vanadium
in relation to morphometric evaluation of preneoplastic lesions
and early DNA damage clearly demonstrate the chemopre-
ventive activity of the pharmacologically effective dose of
vanadium (0.5 ppm) in vivo. All these, taken together, do
justify the chemopreventive role of 0.5 ppm of vanadium in
our chemical rat hepatocarcinogenesis model used in this
study.
Covalent binding or crosslinking of a reactive carcinogen or
its metabolite(s) with the DNA molecule has been postulated to
be the primary event in the initiation phase of chemical
carcinogenesis. DEN, although a potent genotoxic hepatocarci-
nogen, yet cannot interact with the DNA molecule as such until
and unless it is metabolically oxidized and subsequently
decomposes to form the highly reactive alkylating species,
namely ethyl diazonium ion (+N2C2H5) or ethylcarbonium
(+CH3CH2) ion by the CYP2E1 isozyme in rats and humans
[56–58]. Once formed, such electrophilic alkylating agents
attack nucleophilic centers in DNA strands (e.g., N7 and O6 of
guanine moieties) resulting in alkylated/ethylated molecular
adducts, such as e7Gua and O6eGua [59–62]. Replication of
such adducted DNA can bring about mutations in the GC base-
pairs of activated oncogenes leading to carcinogenesis [56,63].
Using the 32P post-labeling assay, we detected here a substantial
level of ethylguanines in hepatic DNA of rats treated with DEN.
The maximum level of adducts was formed 18–20 h following
DEN threat. This is an indicator of the ‘initiation’ event of
carcinogenesis. After that, the tissue levels of adducts declined in
carcinogen challenged liver tissue indicating that, the down-
stream events of chemical carcinogenesis resume after 18–20 h
of DEN threat leading to the development of preneoplastic
phenotype ultimately. We have further noticed a substantial
decrease in the tissue adduct levels following vanadium
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vanadium-mediated inhibition of hepatocarcinogenesis.
Induction of a significant and high steady level of 8-OHdGs
essentially plays a critical role for the activation of carcinogenic
properties of cells [42,64,65]. Using the sensitive HPLC-ECD
method, we detected here a substantial level of 8-OHdGs in
hepatic DNA of rats treated with DEN over the vehicle control
that supported this concept. The maximum level of modified
bases was formed 18–20 h following DEN challenge. This
indicates that 8-OHdG may also have a role in the initiation of
DEN-carcinogenesis besides ethylguanines. Moreover, the
longer maintenance of high levels of 8-OHdGs in liver DNA
could be explained by the exhaustion and/or disturbance of
DNA repair mechanisms leading to further DNA damages, such
as strand-breaks [30,66]. The present investigation showed a
prominent suppressive effect of vanadium at 0.5 ppm dose
on the levels of 8-OHdGs in DEN-challenged rat liver.
Thus, vanadium-mediated reduction of promutagenic lesions
might be important in modulating the initiation process of
hepatocarcinogenesis.
For the cell, double-strand DNA breaks (DSBs) are the most
deleterious form of DNA damage and are generated when the
two complementary stands of the DNA double helix are broken
simultaneously at sites that are sufficiently close to one another
that base-pairing and chromatin structure are insufficient to keep
the two DNA ends juxtaposed. As a consequence, the two DNA
ends generated by a DSB are liable to become physically
dissociated from one another, making ensuing error-prone repair
to take place and providing the opportunity for inappropriate
recombination with other sites in the genome [67,68]. DSBs are
the potent inducers of genomic mutations and of cell death.
Depending upon the severity and extent of DSBs damage, cells
may either choose to arrest the cell-cycle until the damage is
repaired, or if the damage is irreparable, proceed toward
apoptosis [67,69]. Error-prone/inaccurate repair or lack of repair
of DSBs may lead to mutations or to larger-scale chromosomal
aberrations and genomic instability through the generation of
dicentric or acentric chromosomal fragments [67]. Such genome
changes, including translocations, rearrangements, amplifica-
tions, and deletions arising during misrepair may have
tumourigenic potential and may contribute to carcinogenesis.
Several reports and experimental evidences have shown that,
there exists a causal link between the generation of DSBs and the
induction of chromosomal mutations with tumourigenic poten-
tial [67,68,70–75]. In addition, mutations in many of the factors
involved in DSB signaling and repair lead to increased
predisposition to cancer in people and in animal models. Indeed,
defects in cellular responses to DSBsmay be a frequent initiating
event of carcinogenesis [67,70,72]. Moreover, formation of
DSBs from unrepaired SSBs may lead to progression of
preneoplastic tissue towards carcinoma. Thus, SSBs may be
considered as fundamental to the maintenance of chromosome
integrity and genomic stability. The formation of DNA adducts
in conjunction with DNA strand-breaks thus indicates a positive
correlation between these two molecular events, corroborating a
previous report [76]. In the present study, vanadium supple-
mentation resulted in a substantial decrease in the amount of‘tailed’ DNA and DNA ‘comets’ produced by the DEN
treatment. This reduction in DNA damage may reflect the
potential of vanadium to reduce the genotoxic insult caused by
DEN in preneoplastic rat liver.
Conclusively, carcinogen (DEN) insultation to cells may
primarily result in the alkylation of hepatic DNA forming
tissue-specific ethylated DNA adducts which is a critical step in
the initiation of carcinogenesis. DEN-induced alkylation
damage of hepatic DNA may furthermore be reflected in
inducing DNA lesions, such as DNA strand-breaks in rat liver.
Induction of high levels of 8-OHdGs and SSBs may also lead to
chromosome breaks and clastogenesis and genotoxic DNA
damages are the important manifestations of oxidative stress
following carcinogen assault. Oxidative stress has thus been
implicated in the initiation of carcinogenesis. The formation of
8-OHdGs is the result of direct interaction between reactive
oxygen species (ROS), especially hydroxyl radicals (·OH) and
DNA bases [77,78]. Therefore, factors interfering with the
generation of ·OH would affect the formation of 8-OHdGs. In
this study, it was found that low-dose of vanadium pre-treatment
at a concentration of 0.5 ppm in drinking water for 4 weeks
significantly reduced 8-OHdG levels in rat liver, indicating a
protective effect of vanadium against oxidative DNA damage.
Furthermore, in aqueous solution, vanadium is found predomi-
nately as oxo-anions (e.g., VO4
3−) and as such may exhibit
nucleophilic character for the electrophilic agents to attack,
thereby preventing DNA alkylation damage as per the
“carcinogen interception mechanism” proposed by Hamilton
andWilker [79–82]. Recently, this group showed that vanadates
were able to convert ethylating agents and alkylating toxins into
the relatively harmless product ethanol. Their studies suggest
that the design of new compounds for cancer prevention should
incorporate reactive oxo-groups with high anionic charge
density [82]. Thus, the ability of vanadium to attenuate the
formation of tissue-specific DNA adducts in liver may indicate
its broad-spectrum potential to modulate the kinetics of adduct
formation and removal in vivo [81,82]. There is a correlation
between inhibition of carcinogenesis by trace metals and
lowering of carcinogen binding to cells and DNA. These
might involve molecular interactions between metal and
carcinogen at different enzymatic and regulatory sites of target
cells undergoing neoplastic transformation, as well as stimula-
tion of the host immune system [83]. It is well known that DNA
strand-breaks responsible for chromosomal aberrations are
generated from DNA base-lesions induced by most of the
chemical carcinogens; therefore we may assume that the
anticlastogenic effect of vanadium against oxidative DNA
lesions in vivo might be at least due to the promotion of
excision-repair [84,85]. Again, it has also been established that
DSBs are generated from carcinogen-induced DNA lesions in
the S phase of the cell cycle. It has been shown that DSBs are
repaired by the post-replicational repair in the G2 phase and that
unrepaired DSBs result in chromosomal aberrations [67,70–
75]. In this context, we may speculate that vanadium might have
a role in the modification of the capability of the post-
replicational repair of DSBs. Recent works of Zhang et al. [86]
have shown that vanadium is able to induce S and G2-M phase
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through activation of p53- and p21-dependent pathways, and
may thus prolong the repair mechanisms of oxidative DNA
lesions and breakage-type aberrations. However, elucidation of
the mechanistic insights into the vanadium-mediated DNA
repair pathways remains our future course of study.
Taken together, the study indicates the potential role of
vanadium in limiting the initiation event of hepatocarcinogen-
esis in rats. The study further reflects the interactions of
vanadium with the critical molecule DNA, thereby interfering
with the formation of DNA adducts and subsequent DNA
lesions. This may result in the enhancement of the chemopre-
ventive potential of this trace element in inhibiting the initiation
event and thereby limiting genotoxicity during the early stages
of hepatocellular transformation in rats. The intricate molecular
mechanisms behind the potential anticarcinogenic action of
vanadium, particularly in modulating the initiation events
warrant a thorough investigation and our present research is
focused in this particular direction.
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